UK Health Check-up Market Size, Share & Trends Analysis Report By Test Type (Blood, Urine, Body Fluid Tests, Imaging-based Tests), By End-use (Enterprise, Individual), And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
UK Health Check-up Market Growth & Trends
The UK health check-up market size is anticipated t%li%reach USD 3.0 billion by 2030, growing at a CAGR of 6.08% from 2024 t%li%2030, according t%li%a new report by Grand View Research, Inc. The market is driven by the rising prevalence of chronic diseases and the need t%li%provide preventive screening solutions. For instance, according t%li%UK Health indicators, the top four most prevalent chronic conditions in the UK for both men and women are allergies, hypertension, lower back disorders, and depression. Allergies emerged as the most frequently reported chronic issue among both genders, with rates of 30.4% for men and 36.0% for women. Nearly half of the UK population, comprising 45.7% of men and 50.1% of women, disclosed experiencing a persistent condition. A higher proportion of women (22.3%) indicated experiencing some activity limitations due t%li%health issues in the past six months compared t%li%men (18.5%).
Rising government initiatives t%li%provide healthcare solutions is further anticipated t%li%drive market growth. For instance, in February 2024, the National Health Service (NHS) announce the launch of a digital version of the health check-up program for citizens in England. This initiative, known as the NHS Health Check, is designed for individuals aged 40 t%li%74, which translates t%li%approximately 15 million people across the country. The check-up process typically involves an appointment with a general practitioner (GP), where patients are assessed for potential risks related t%li%type 2 diabetes, strokes, kidney disease, and certain forms of dementia.
Moreover, the introduction of telemedicine in general healthcare practices has fueled the demand for home-based testing solutions. The healthcare ecosystem's digital connectivity framework has further empowered the market during the COVID-19 pandemic. The rising incidence of life-threatening diseases is a major driver for the market. This includes the growing prevalence of non-communicable diseases, such as diabetes, hypertension, cancer, and cardiovascular diseases. This combination of the increased availability of telemedicine and home-based testing, the escalating prevalence of life-threatening diseases, and the need for early detection of asymptomatic conditions are collectively expected t%li%drive the growth and expansion of the market. These factors have enabled individuals t%li%manage their health proactively and have contributed t%li%the overall development of the healthcare ecosystem during the COVID-19 pandemic and beyond.
Furthermore, the rising strategic initiatives undertaken by the key players in the market, such as enhancing healthcare services and fostering collaborations between the public and private sectors, are expected t%li%drive the overall development and expansion of the market. Additionally, the introduction of direct-to-customer testing solutions is anticipated t%li%contribute t%li%the growth and accessibility of check-up services during the forecast period. For instance, in June 2023, NHS announced the launch of home-based digital health checks. This new digital health check has been introduced with the aim of delivering an additional one million checks in the first four years.
UK Health Check-up Market Report Highlights
UK Health Check-up Market Growth & Trends
The UK health check-up market size is anticipated t%li%reach USD 3.0 billion by 2030, growing at a CAGR of 6.08% from 2024 t%li%2030, according t%li%a new report by Grand View Research, Inc. The market is driven by the rising prevalence of chronic diseases and the need t%li%provide preventive screening solutions. For instance, according t%li%UK Health indicators, the top four most prevalent chronic conditions in the UK for both men and women are allergies, hypertension, lower back disorders, and depression. Allergies emerged as the most frequently reported chronic issue among both genders, with rates of 30.4% for men and 36.0% for women. Nearly half of the UK population, comprising 45.7% of men and 50.1% of women, disclosed experiencing a persistent condition. A higher proportion of women (22.3%) indicated experiencing some activity limitations due t%li%health issues in the past six months compared t%li%men (18.5%).
Rising government initiatives t%li%provide healthcare solutions is further anticipated t%li%drive market growth. For instance, in February 2024, the National Health Service (NHS) announce the launch of a digital version of the health check-up program for citizens in England. This initiative, known as the NHS Health Check, is designed for individuals aged 40 t%li%74, which translates t%li%approximately 15 million people across the country. The check-up process typically involves an appointment with a general practitioner (GP), where patients are assessed for potential risks related t%li%type 2 diabetes, strokes, kidney disease, and certain forms of dementia.
Moreover, the introduction of telemedicine in general healthcare practices has fueled the demand for home-based testing solutions. The healthcare ecosystem's digital connectivity framework has further empowered the market during the COVID-19 pandemic. The rising incidence of life-threatening diseases is a major driver for the market. This includes the growing prevalence of non-communicable diseases, such as diabetes, hypertension, cancer, and cardiovascular diseases. This combination of the increased availability of telemedicine and home-based testing, the escalating prevalence of life-threatening diseases, and the need for early detection of asymptomatic conditions are collectively expected t%li%drive the growth and expansion of the market. These factors have enabled individuals t%li%manage their health proactively and have contributed t%li%the overall development of the healthcare ecosystem during the COVID-19 pandemic and beyond.
Furthermore, the rising strategic initiatives undertaken by the key players in the market, such as enhancing healthcare services and fostering collaborations between the public and private sectors, are expected t%li%drive the overall development and expansion of the market. Additionally, the introduction of direct-to-customer testing solutions is anticipated t%li%contribute t%li%the growth and accessibility of check-up services during the forecast period. For instance, in June 2023, NHS announced the launch of home-based digital health checks. This new digital health check has been introduced with the aim of delivering an additional one million checks in the first four years.
UK Health Check-up Market Report Highlights
- Blood, urine, body fluid tests segment dominated the test type segment and is anticipated t%li%grow at the fastest growth rate over the forecast period owing t%li%the rising adoption and usage of blood, urine, and body fluid samples in preventive care diagnosis.
- Individuals dominated the end-use segment; this is attributed t%li%the growing awareness for preventive health among the population.
- Out-of-pocket dominated the individual end-use segment owing t%li%the rising out-of-pocket spending expenditure by customers for personal check-ups.
- Enterprise segment held a significant share in end-use segment owing t%li%the growing number of companies providing insurance t%li%their employees.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test Type
1.2.2. End-use
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test Type and End-use outlook
2.3. Competitive Insights
CHAPTER 3. UK HEALTH CHECK-UP MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of diseases
3.2.1.2. Growing investments in population screening
3.2.1.3. Growing geriatric population
3.2.1.4. Adoption of digital technology
3.2.2. Market Restraint Analysis
3.2.2.1. High cost associated with screening
3.2.2.2. Psychological Factors And Knowledge, Attitudes, & Beliefs
3.2.3. Market challenge analysis
3.2.3.1. Lack of awareness
3.2.4. Market Opportunity Analysis
3.2.4.1. Rising medical tourism
3.3. UK Health Check-up Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. UK HEALTH CHECK-UP MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
4.1. UK Health Check-up Market: Test Type Dashboard
4.2. UK Health Check-up Market: Test Type Movement Analysis
4.3. UK Health Check-up Market by Test Type, Revenue
4.4. Blood, Urine, Body Fluid Tests
4.4.1. Blood, urine, body fluid tests market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Imaging-based tests (Xray, CT, US, MRI)
4.5.1. Imaging based tests (Xray, CT, US, MRI) market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Non-imaging Tests (ECG, CPET, NCS, EMG, EEG)
4.6.1. Non-imaging tests (ECG, CPET, NCS, EMG, EEG) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. UK HEALTH CHECK-UP MARKET: END-USE ESTIMATES & TREND ANALYSIS
5.1. UK Health Check-up Market: End-use Dashboard
5.2. UK Health Check-up Market: End-use Movement Analysis
5.3. UK Health Check-up Market by End-use, Revenue
5.4. Enterprise
5.4.1. Enterprise market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Private (Corporate) Sector
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Government Sector
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Insurance
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Individual
5.5.1. Individual market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Out of Pocket- Direct Payment for Health Check
5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. Individual Health Insurance Plan
5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2023
6.3.4. Quest Diagnostics Incorporated
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Laboratory Corporation of America Holdings
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. SYNLAB International GmbH
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. OPKO Health, Inc.
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Eurofins Scientific
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. UNILABS
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Sonic Healthcare Limited
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. ARUP Laboratories
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Q2 Solutions
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test Type
1.2.2. End-use
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test Type and End-use outlook
2.3. Competitive Insights
CHAPTER 3. UK HEALTH CHECK-UP MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of diseases
3.2.1.2. Growing investments in population screening
3.2.1.3. Growing geriatric population
3.2.1.4. Adoption of digital technology
3.2.2. Market Restraint Analysis
3.2.2.1. High cost associated with screening
3.2.2.2. Psychological Factors And Knowledge, Attitudes, & Beliefs
3.2.3. Market challenge analysis
3.2.3.1. Lack of awareness
3.2.4. Market Opportunity Analysis
3.2.4.1. Rising medical tourism
3.3. UK Health Check-up Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. UK HEALTH CHECK-UP MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
4.1. UK Health Check-up Market: Test Type Dashboard
4.2. UK Health Check-up Market: Test Type Movement Analysis
4.3. UK Health Check-up Market by Test Type, Revenue
4.4. Blood, Urine, Body Fluid Tests
4.4.1. Blood, urine, body fluid tests market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Imaging-based tests (Xray, CT, US, MRI)
4.5.1. Imaging based tests (Xray, CT, US, MRI) market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Non-imaging Tests (ECG, CPET, NCS, EMG, EEG)
4.6.1. Non-imaging tests (ECG, CPET, NCS, EMG, EEG) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. UK HEALTH CHECK-UP MARKET: END-USE ESTIMATES & TREND ANALYSIS
5.1. UK Health Check-up Market: End-use Dashboard
5.2. UK Health Check-up Market: End-use Movement Analysis
5.3. UK Health Check-up Market by End-use, Revenue
5.4. Enterprise
5.4.1. Enterprise market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Private (Corporate) Sector
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Government Sector
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Insurance
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Individual
5.5.1. Individual market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Out of Pocket- Direct Payment for Health Check
5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. Individual Health Insurance Plan
5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2023
6.3.4. Quest Diagnostics Incorporated
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Laboratory Corporation of America Holdings
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. SYNLAB International GmbH
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. OPKO Health, Inc.
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Eurofins Scientific
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. UNILABS
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Sonic Healthcare Limited
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. ARUP Laboratories
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Q2 Solutions
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 UK health check-up market, by test type, 2018 - 2030 (USD Million)
Table 3 UK health check-up market, by end-use, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 UK health check-up market, by test type, 2018 - 2030 (USD Million)
Table 3 UK health check-up market, by end-use, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Head And neck cancer therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Therapy type and route of administration segment snapshot
Fig. 11 Distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
Fig. 24 Global oral market, 2018 - 2030 (USD Million)
Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key country dynamics
Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 37 Key country dynamics
Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 40 Key country dynamics
Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 45 Key country dynamics
Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Oropharynx cancer incidence, 2020 - 2030
Fig. 48 Germany insurance coverage
Fig. 49 Key country dynamics
Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 52 Key country dynamics
Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 55 Key country dynamics
Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Larynx cancer incidence, 2020 - 2030
Fig. 58 Key country dynamics
Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
Fig. 61 Key country dynamics
Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 64 Key country dynamics
Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Japan pharmaceutical registration
Fig. 72 Key country dynamics
Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
Fig. 75 Regulatory details: China
Fig. 76 Exclusivity formula
Fig. 77 Key country dynamics
Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 80 Registration details: India
Fig. 81 Key country dynamics
Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
Fig. 84 Drug pricing: Australia
Fig. 85 Contribution of PBS by disease
Fig. 86 Key country dynamics
Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
Fig. 89 Key country dynamics
Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
Fig. 92 Reimbursement scenario: South Korea
Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Larynx Cancer Incidence, 2020 to 2030
Fig. 98 Regulatory framework
Fig. 99 Reimbursement scenario
Fig. 100 Key country dynamics
Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Larynx cancer incidence, 2020 to 2030
Fig. 105 Argentina pharmaceuticals registration details
Fig. 106 Argentina pharmaceuticals reimbursement details
Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 112 Regulatory framework: South Africa
Fig. 113 Regulatory framework: South Africa drug registration fees
Fig. 114 Key country dynamics
Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
Fig. 117 Key country dynamics
Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 120 Key country dynamics
Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 123 Regulatory framework: Kuwait
Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 125 Key company categorization
Fig. 126 Company market share analysis, 2023
Fig. 127 Strategic framework
Fig. 1 Head And neck cancer therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Therapy type and route of administration segment snapshot
Fig. 11 Distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
Fig. 24 Global oral market, 2018 - 2030 (USD Million)
Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key country dynamics
Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 37 Key country dynamics
Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 40 Key country dynamics
Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 45 Key country dynamics
Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Oropharynx cancer incidence, 2020 - 2030
Fig. 48 Germany insurance coverage
Fig. 49 Key country dynamics
Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 52 Key country dynamics
Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 55 Key country dynamics
Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Larynx cancer incidence, 2020 - 2030
Fig. 58 Key country dynamics
Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
Fig. 61 Key country dynamics
Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 64 Key country dynamics
Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Japan pharmaceutical registration
Fig. 72 Key country dynamics
Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
Fig. 75 Regulatory details: China
Fig. 76 Exclusivity formula
Fig. 77 Key country dynamics
Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 80 Registration details: India
Fig. 81 Key country dynamics
Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
Fig. 84 Drug pricing: Australia
Fig. 85 Contribution of PBS by disease
Fig. 86 Key country dynamics
Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
Fig. 89 Key country dynamics
Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
Fig. 92 Reimbursement scenario: South Korea
Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Larynx Cancer Incidence, 2020 to 2030
Fig. 98 Regulatory framework
Fig. 99 Reimbursement scenario
Fig. 100 Key country dynamics
Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Larynx cancer incidence, 2020 to 2030
Fig. 105 Argentina pharmaceuticals registration details
Fig. 106 Argentina pharmaceuticals reimbursement details
Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 112 Regulatory framework: South Africa
Fig. 113 Regulatory framework: South Africa drug registration fees
Fig. 114 Key country dynamics
Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
Fig. 117 Key country dynamics
Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 120 Key country dynamics
Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 123 Regulatory framework: Kuwait
Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 125 Key company categorization
Fig. 126 Company market share analysis, 2023
Fig. 127 Strategic framework
